Deciphera Pharmaceuticals, Inc. (DCPH)

NASDAQ: DCPH · IEX Real-Time Price · USD
13.22
-0.13 (-0.97%)
Dec 5, 2023, 11:00 AM EST - Market open
-0.97%
Market Cap 1.07B
Revenue (ttm) 151.41M
Net Income (ttm) -193.69M
Shares Out 80.12M
EPS (ttm) -2.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 63,573
Open 13.32
Previous Close 13.35
Day's Range 13.05 - 13.32
52-Week Range 9.90 - 22.76
Beta 0.50
Analysts Buy
Price Target 22.56 (+70.65%)
Earnings Date Oct 30, 2023

About DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switc... [Read more]

Sector Healthcare
IPO Date Sep 28, 2017
Employees 300
Stock Exchange NASDAQ
Ticker Symbol DCPH
Full Company Profile

Financial Performance

In 2022, DCPH's revenue was $134.04 million, an increase of 39.41% compared to the previous year's $96.15 million. Losses were -$178.93 million, -40.35% less than in 2021.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for DCPH stock is "Buy." The 12-month stock price forecast is $22.56, which is an increase of 70.65% from the latest price.

Price Target
$22.56
(70.65% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

6 days ago - Business Wire

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

4 weeks ago - Business Wire

Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

5 weeks ago - Business Wire

Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

5 weeks ago - Business Wire

Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

2 months ago - Business Wire

Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

4 months ago - Business Wire

Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D.

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

4 months ago - Business Wire

Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

4 months ago - Business Wire

Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

6 months ago - Business Wire

Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

7 months ago - Business Wire

Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

7 months ago - Business Wire

Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

7 months ago - Business Wire

Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

8 months ago - Business Wire

Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

9 months ago - Business Wire

Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

9 months ago - Business Wire

Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results

Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results

10 months ago - Business Wire

Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improv...

11 months ago - Business Wire

Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improv...

11 months ago - Business Wire

Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improv...

11 months ago - Business Wire

Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improv...

11 months ago - Business Wire

Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improv...

11 months ago - Business Wire

Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improv...

11 months ago - Business Wire

Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improv...

11 months ago - Business Wire

Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan...

1 year ago - Business Wire